english.prescrire.org

Subscribe to Prescrire International
  
 Follow us
TwitterFacebook
 

In Prescrire's Spotlight

Good sources

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Ivacaftor + tezacaftor + elexacaftor (Kaftrio°) in cystic fibrosis with at least one delta F508 mutation from 6 years of age

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Drug-induced impairment of lactation

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Proving a treatment's efficacy

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Difelikefalin (Kapruvia°) in pruritus associated with chronic kidney disease

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Prescrire's finances: 2022 annual report

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a booster

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Enjoy these features, and more, in our upcoming issues

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic

1 June 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
New! "Top Texts of 2022", from the editors of Prescrire International

1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Subscribe today for full access to top-quality content from Prescrire International

1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Follow Prescrire International on Facebook and Twitter

1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Receive the free, monthly "Independent Drug & Healthcare Newsletter"

1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Drugs to avoid, in the name of better patient care

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Read more All the subjects in Prescrire's Spotlight >